(Total Views: 529)
Posted On: 10/12/2021 12:42:52 PM
Post# of 153940
The most salient point in the article, as far as Leronlimab is concerned, is noted at the end of the article.
"Moreover, the same thing that makes the virus more infectious- faster replication or TIGHTER BINDING TO OUR CELLS (emphasis added) could also make it more virulent."
Well, isn't that the theory of Leronlimab's effectiveness...this MAB acts as a shield against such binding? The era of COVID-19 will require effective modalities of treatment. Trial on CYTODYN!
"Moreover, the same thing that makes the virus more infectious- faster replication or TIGHTER BINDING TO OUR CELLS (emphasis added) could also make it more virulent."
Well, isn't that the theory of Leronlimab's effectiveness...this MAB acts as a shield against such binding? The era of COVID-19 will require effective modalities of treatment. Trial on CYTODYN!
(3)
(0)
